Edwards Lifesciences (EW) Faces Investor Class Action Over Loss of $16 Billion Of Market Capitalization – Hagens Berman

Core Viewpoint - Edwards Lifesciences Corporation is facing a class action lawsuit due to allegations of misleading investors regarding the growth prospects of its Transcatheter Aortic Valve Replacement (TAVR) platform [1][3]. Group 1: Company Disclosures and Performance - Throughout the class period, Edwards Lifesciences assured investors of "strong sustainable growth" for the TAVR platform, projecting healthy double-digit growth and the potential for acceleration in 2025 and beyond [2]. - The company later revealed that TAVR sales grew only 5% and reduced its growth guidance from 8-10% to 5-7% [4]. - The decline in TAVR growth was attributed to increased competition from structural heart therapies, which impacted hospital workflows [4]. Group 2: Investor Reactions and Market Impact - Following the disappointing Q2 2024 results, analysts downgraded Edwards Lifesciences shares and lowered their price targets, questioning the company's explanations regarding physician capacity versus demand [4]. - The share price dropped by $27.25, a decrease of 31%, resulting in a loss of over $16 billion in shareholder value in a single day [4]. Group 3: Legal and Investigative Actions - Hagens Berman is investigating whether Edwards Lifesciences misled investors about the TAVR business and growth prospects amid increasing competition [5]. - The firm encourages investors who suffered losses to submit their claims and provides information for whistleblowers with non-public information [5].